Grădinaru Raluca Claudia, Andreescu Nicoleta Ioana, Nussbaum Laura Alexandra, Farcaş Simona Sorina, Dumitraşcu Victor, Suciu Liana, Puiu Maria
Discipline of Medical Genetics, Department of Microscopic Morphology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania;
Rom J Morphol Embryol. 2016;57(4):1343-1349.
We aim to investigate whether the -759C÷T polymorphism in 5-HTR2C gene was associated with weight change and hyperinsulinemia in Romanian pediatric patients with schizophrenia and bipolar disorders. The patients under investigation were enrolled between 2009 and 2014. A total of 81 schizophrenic and bipolar-disorder patients, aged between nine to 20 years (median age 15.74±4 years), who were following an atypical antipsychotic treatment (Risperidone, Aripiprazole, Olanzapine), were enrolled from University Hospital for Child and Adolescent Psychiatry and Neurology from Timisoara, Romania. The outcomes that we measured were the changes in Body Mass Index (BMI) from baseline to different time points: three months, six months, 12 months and 18 months, and the change in insulinemia over time, after atypical antipsychotic treatment. After carrying out the 5-HTR2C 759C÷T polymorphism identification, we found that 22 patients presented the -759C÷T polymorphism in 5-HTR2C gene. Between the patients exhibiting the 5-HTR2C -759C÷T polymorphism and the patients having the wild type alleles, there was no significant statistical difference in changes of BMI from baseline to endpoints that indicates the lack of the protective effect of the T allele against atypical antipsychotics-induced weight gain. Interestingly, we found a statistically significant association between insulinemia and T alleles' carriers, after 18 months of treatment with the above-mentioned antipsychotics. Taking into consideration that atypical antipsychotics have been associated with elevated insulin levels and insulin resistance, maybe in the future the -759C÷T polymorphism would find a role in the development of a more complex algorithm for prediction of diabetes mellitus risk, in patients taking atypical antipsychotics.
我们旨在研究5-羟色胺2C型受体（5-HTR2C）基因中的-759C÷T多态性是否与罗马尼亚患精神分裂症和双相情感障碍的儿科患者的体重变化及高胰岛素血症相关。被调查的患者于2009年至2014年期间入组。共有81名年龄在9至20岁（中位年龄15.74±4岁）、正在接受非典型抗精神病药物治疗（利培酮、阿立哌唑、奥氮平）的精神分裂症和双相情感障碍患者，从罗马尼亚蒂米什瓦拉的儿童与青少年精神病学及神经学大学医院入组。我们所测量的结果是从基线到不同时间点（三个月、六个月、12个月和18个月）的体重指数（BMI）变化，以及在接受非典型抗精神病药物治疗后随时间变化的胰岛素血症情况。在进行5-HTR2C 759C÷T多态性鉴定后，我们发现22名患者存在5-HTR2C基因中的-759C÷T多态性。在表现出5-HTR2C -759C÷T多态性的患者与具有野生型等位基因的患者之间，从基线到终点的BMI变化没有显著统计学差异，这表明T等位基因对非典型抗精神病药物引起的体重增加缺乏保护作用。有趣的是，在用上述抗精神病药物治疗18个月后，我们发现胰岛素血症与T等位基因携带者之间存在统计学上的显著关联。考虑到非典型抗精神病药物与胰岛素水平升高和胰岛素抵抗有关，也许在未来，-75 /C÷T多态性在为服用非典型抗精神病药物的患者开发更复杂的糖尿病风险预测算法中会发挥作用。
